Evonik stock trades in the high teens as 2026 rally meets cautious analyst targets

Evonik Industries AG (ISIN DE000EVNK013) stock is quoted in the high teens in EUR as of August 18, 2026, extending a strong year-to-date recovery that has lifted the shares more than 34 percent compared with the start of 2026. Per recent market data compiled on August 18, 2026, Evonik stock trades around EUR 18.14 on a German venue with a same-day gain of 0.89 percent and a year-to-date performance of 34.78 percent, underlining how the specialty chemicals group has rebuilt investor confidence this year after a weaker phase in prior periods. For investors, the current price zone matters because it sits close to the latest closing levels while consensus targets imply only modest further upside.

Price action and 2026 performance

Recent quote snapshots published on August 18, 2026 show Evonik shares changing hands at EUR 18.14, with the intraday move of 0.89 percent pointing to a constructive but measured advance rather than a sharp swing. The same overview indicates that the year-to-date change stands at 34.78 percent relative to January 1, 2026, confirming that most of the stock’s progress this year has already been booked by mid-August. A separate price summary for the stock’s last close lists a closing level of EUR 18.08 on August 17, 2026, which places the current quote only EUR 0.06 above that reference and signals consolidation within a tight range after the rally earlier in the year.

Analyst data compiled alongside the latest price figures put the average target price for Evonik at EUR 18.28, only EUR 0.20 above the most recent close at EUR 18.08. That small gap between the last closing price and the consensus target signals that the market’s expectations are now more balanced, with limited room for further gains unless earnings or guidance surprise positively in the coming quarters. The comparison between the current quote at EUR 18.14 and the target at EUR 18.28 also shows that Evonik stock is trading close to what analysts currently regard as fair value, which makes operational execution and margin trends critical for the next leg of the share price story.

Recent fundamentals and analyst view

While the most recent full quarterly or half-year figures are not detailed in the available same-day summaries, the current consensus view reflected in the EUR 18.28 target price suggests that analysts expect Evonik to deliver stable earnings and cash flows rather than dramatic swings in profitability. The fact that the target price sits only 1.1 percent above the latest close implies that recent results and guidance have aligned reasonably well with expectations, leaving little valuation discount to compensate for potential disappointments. In this context, the stock’s robust 34.78 percent year-to-date gain in 2026 looks like a front-loaded reaction to improving demand patterns, portfolio measures and cost discipline that were already visible in earlier reporting periods, while incremental upside now depends more on incremental beats or strategic catalysts.

From an income perspective, a same-day market overview indicates that Evonik currently offers a dividend yield of 5.53 percent based on its recent payout and prevailing share price. This yield level, paired with the high-teens EUR price zone and steady analyst targets, positions the stock as a blend of recovery and income exposure within the European specialty chemicals space. The combination of a mid-single-digit dividend yield and a rally of more than 34 percent year-to-date means that total return for 2026 so far has been compelling, but it also raises the bar for future performance as investors weigh whether margins, volumes and free cash flow can sustain both the payout and the new, higher share price plateau.

Valuation context and 52-week positioning

The available consensus overview points to Evonik’s last close of EUR 18.08 as of August 17, 2026, combined with an average target of EUR 18.28 and a positive year-to-date change of 35.93 percent in one cited series. Taken together, these data sets indicate that the share price has climbed from the low teens into the high teens EUR area over the course of 2026, moving closer to the upper end of its recent trading history. While a detailed 52-week range is not specified in the visible excerpts, the strong year-to-date percentage gain strongly implies that current levels are significantly higher than those seen in late 2025 and early 2026, when the sector faced softer demand and margin pressure.

For valuation-focused investors, the narrow spread between the current quote and analyst targets underscores that Evonik is no longer trading at a deep discount to its peers in specialty chemicals. Instead, the stock now seems priced for moderate growth and stable returns, with the dividend yield of 5.53 percent providing a cushion but not an unlimited buffer against potential cyclical swings. In quantitative terms, the roughly 0.20 EUR difference between the EUR 18.08 close and the EUR 18.28 target is small relative to the 6-Euro-plus upside the shares have already captured since early 2026, which frames the present phase more as consolidation and assessment than as the beginning of a new explosive rally.

Business profile and specialty chemicals focus

Evonik Industries AG operates as a diversified specialty chemicals company, using a holding structure to manage a portfolio of businesses that supply functional chemicals, additives and materials to industrial, consumer and advanced-technology end markets. According to its company profile, Evonik’s activities span areas such as performance materials, nutrition and care solutions, and resource efficiency products, which are often tailored to customer needs and carry higher margin potential than basic commodity chemicals. This focus on specialty chemicals means that Evonik’s earnings and cash flows depend not only on global macro demand but also on its ability to innovate, differentiate and maintain strong relationships across its value chains.

The company’s strategic emphasis on specialties also shapes how investors interpret its stock metrics. Higher-margin product lines and solutions tend to support steadier profitability and a more resilient earnings profile, which justifies a valuation closer to fair value after a strong year-to-date run, rather than a distressed multiple. Conversely, when end markets soften or input costs move against the company, the impact on earnings can be pronounced because customers may delay orders for value-added products. In this context, consensus targets that cluster close to the current price reflect a balance between confidence in Evonik’s specialty positioning and caution regarding cyclical risks and global industrial demand.

Representative product and applications

One representative dimension of Evonik’s business is its portfolio of specialty additives and performance materials that enhance the properties of plastics, coatings, and industrial formulations. These products are engineered to improve characteristics such as durability, flexibility, resistance to environmental stress and processing efficiency, making them integral to customers’ manufacturing processes and the performance of end products. By supplying tailor-made additives for sectors such as automotive, construction, electronics and consumer goods, Evonik embeds itself deeply in its customers’ value chains and gains opportunities to capture recurring, higher-margin revenue streams.

In practice, Evonik’s performance materials are used to make lightweight yet robust components, more efficient insulation materials, and advanced coatings that extend product lifetimes or reduce energy consumption. This application focus ties the company’s fortunes to trends like energy efficiency, sustainability, and lightweight design, themes that remain highly relevant for global industry in 2026. For stock investors, understanding these product-level dynamics helps explain why Evonik’s valuation can support a significant rally when demand is strong: the company is not only selling volumes but also value via technology and performance enhancements, which can translate into attractive margins and cash flows when executed effectively.

Closing view on Evonik stock

Evonik stock currently trades close to its latest closing level, with recent data pointing to a quote of EUR 18.14 on August 18, 2026 after a previous close of EUR 18.08, and a year-to-date gain between 34.78 percent and 35.93 percent depending on the specific series consulted. With an average analyst target at EUR 18.28 and a dividend yield of 5.53 percent, the shares now sit in a price zone that reflects their 2026 recovery and income appeal while leaving only modest implied upside, making future earnings reports and margin developments the key drivers for any next decisive move.

Read more

Further coverage of Evonik stock and related market data is available in a same-day overview that summarizes recent price performance, analyst targets and dividend metrics.

Fact box

Company: Evonik Industries AG

ISIN: DE000EVNK013

Ticker: EVK

Exchange: Xetra

Sector / Industry: Specialty chemicals